Cerebral Small Vessel Disease Registry Study
ConditionCerebral Small Vessel Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorBin Cai
About this trial
The aim of this study is to determine the clinical spectrum and natural progression of Cerebral Small Vessel Disease (CSVD) and in a prospective multicenter study, to assess the clinical, genetic and epigenetic features of patients with CSVD, , to find independent imaging markers, and to optimize clinical management.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Sign informed consent.
Age>18
At least one of the following CSVD MRI characteristics: ①recent small subcortical infarct;②lacune of presumed vascular origin;③white matter hypertensity of presumed vascular origin;④perivascular space;⑤cerebral microbleeds;⑥brain atrophy
Disqualifiers
Unable to cooperate with inspectors
Non-vascular white matter lesions
Other cognitive diseases (such as alzheimer's disease, Parkinson's disease or thyroid disease)
Serious systemic illness, such as heart, liver, kidney disease or major mental illness
Trial population
Patient who are diagnosed as Cerebral Small Vessel Disease
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall outcomes in patients with cerebral small vessel disease.
record the occurrence of stroke and use modified Rankin Scale (mRS) to measure the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
Time frame
From date of enrollment until the date of death from any cause, assessed up to 30 yearsSecondary outcomes
1
the development of the burden of microbleeds in MRI
using MARS scale to evaluate the development of the burden of microbleeds
Time frame
From date of enrollment until the date of death from any cause, assessed up to 30 years2
the development of the burden of white matter hypertension in MRI
using Fazakes scale to evaluate the development of the burden of white matter hypertension
Time frame
From date of enrollment until the date of death from any cause, assessed up to 30 years3
the development of lacunes in MRI
record the number and location of lacunes
Time frame
From date of enrollment until the date of death from any cause, assessed up to 30 years4
the development of enlarged perivascular space in MRI
record the number and location of enlarged perivascular space
Time frame
From date of enrollment until the date of death from any cause, assessed up to 30 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Bin Cai
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Sponsor institution
Source ClinicalTrials.gov